Evidence map›Paper›PMID 26254483›Full record

ArticleJournal of biochemistry2016

Effect of trastuzumab interchain disulfide bond cleavage on Fcγ receptor binding and antibody-dependent tumour cell phagocytosis.

Mami Suzuki, Ayaka Yamanoi, Yusuke Machino, Michiko Ootsubo, Ken-ichi Izawa, Junya Kohroki, Yasuhiko Masuho

Open access · bronzeAbstract read
In one paragraph

Article in Journal of biochemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Mami SuzukiFaculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Chiba 278-8510, Japan and Teijin Pharma Limited, 4-3-2 Asahigaoka, Hino-shi, Tokyo 191-8512, Japan mam.suzuki@teijin.co.jp.
Ayaka YamanoiFaculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Chiba 278-8510, Japan and.
Yusuke MachinoFaculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Chiba 278-8510, Japan and.
Michiko OotsuboFaculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Chiba 278-8510, Japan and.
Ken-ichi IzawaFaculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Chiba 278-8510, Japan and.
Junya KohrokiFaculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Chiba 278-8510, Japan and.
Yasuhiko MasuhoFaculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Chiba 278-8510, Japan and.
Tokyo University of Science · JPTeijin (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Fc domain of human IgG1 binds to Fcγ receptors (FcγRs) to induce effector functions such as phagocytosis. There are four interchain disulfide bonds between the H and L chains. In this study, the disulfide bonds within the IgG1 trastuzumab (TRA), which is specific for HER2, were cleaved by mild S-sulfonation or by mild reduction followed by S-alkylation with three different reagents. The cleavage did not change the binding activities of TRA to HER2-bearing SK-BR-3 cells. The binding activities of TRA to FcγRIIA and FcγRIIB were greatly enhanced by modification with mild reduction and S-alkylation with ICH2CONH2 or N-(4-aminophenyl) maleimide, while the binding activities of TRA to FcγRI and FcγRIIIA were decreased by any of the four modifications. However, the interchain disulfide bond cleavage by the different modifications did not change the antibody-dependent cell-mediated phagocytosis (ADCP) of SK-BR-3 cells by activated THP-1 cells. The order of FcγR expression levels on the THP-1 cells was FcγRII > FcγRI > FcγRIII and ADCP was inhibited by blocking antibodies against FcγRI and FcγRII. These results imply that the effect of the interchain disulfide bond cleavage on FcγRs binding and ADCP is dependent on modifications of the cysteine residues and the FcγR isotypes.

Indexed as

Antibody-Dependent Cell CytotoxicityCytophagocytosisAlkylationAntibody AffinityAntineoplastic AgentsCell Line, TumorErb-b2 Receptor Tyrosine KinasesHumansImmunoglobulin GIodoacetamideMaleimidesNeoplasmsProtein Structure, SecondaryReceptors, IgGTrastuzumabAntineoplastic AgentsERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesImmunoglobulin GIodoacetamideMaleimidesN-(4-aminophenyl)maleimideReceptors, IgGTrastuzumabFcγ receptorsIgG1interchain disulfide bondsphagocytosistrastuzumab

Identifiers

PMID26254483
PMCPMC4882641
OpenAlexW2293056973

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.